Pharmaceutical technology company Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) on Wednesday announced its financial consolidated results for the six months ended 30 June 2025.

Innocan said that this period delivered a positive swing in its operating profitability and continued strengthening of its balance sheet.

Revenues decreased by 4% in the first half of 2025 to USD14.8m, from USD15.4m in the first half of 2024, attributed to uncertainty in the markets as a result of global trade tariffs.

Gross profit was down 4.9% to USD13.3m, compared to USD14.m in the first half of last year, while operating profit increased by 130% to USD0.885m, from an operating loss of USD0.680m a year earlier.